Nikita Shah - Amneal Pharmaceuticals Insider

2DT Stock  EUR 7.30  0.05  0.69%   

Insider

Nikita Shah is Chief Human Resource Officer, Senior Vice President of Amneal Pharmaceuticals since 2018.
Age 45
Tenure 6 years
Phone908 947 3120
Webhttps://www.amneal.com

Nikita Shah Latest Insider Activity

Tracking and analyzing the buying and selling activities of Nikita Shah against Amneal Pharmaceuticals stock is an integral part of due diligence when investing in Amneal Pharmaceuticals. Nikita Shah insider activity provides valuable insight into whether Amneal Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Amneal Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Amneal Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Amneal Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0257 % which means that it generated a profit of $0.0257 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8759) %, meaning that it generated substantial loss on money invested by shareholders. Amneal Pharmaceuticals' management efficiency ratios could be used to measure how well Amneal Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Amneal Pharmaceuticals has accumulated 2.72 B in total debt with debt to equity ratio (D/E) of 7.78, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amneal Pharmaceuticals has a current ratio of 2.4, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Amneal Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Amneal Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amneal Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amneal to invest in growth at high rates of return. When we think about Amneal Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Nicholas FCAInternational Consolidated Airl
57
Francene CPAComputer And Technologies
58
Michael FinleyMicrochip Technology Incorporat
N/A
Achileas ConstantakopoulosAEGEAN AIRLINES
N/A
Ka PoonComputer And Technologies
56
Vincent HodderInternational Consolidated Airl
51
Tetsuo KashioCasio Computer CoLtd
N/A
Sajid DaudiMicrochip Technology Incorporat
N/A
Nobuyuki MochinagaCasio Computer CoLtd
N/A
David PodolskyInternational Consolidated Airl
N/A
Yamynn DeAngelisComputer And Technologies
66
John GibbsInternational Consolidated Airl
N/A
Luis MartinInternational Consolidated Airl
N/A
Tetsuro IzumiCasio Computer CoLtd
N/A
Allen NicholsonComputer And Technologies
56
Kwok NgComputer And Technologies
48
David BragerComputer And Technologies
55
Robert BanisComputer And Technologies
N/A
Sarah ClementsInternational Consolidated Airl
N/A
Takashi KashioCasio Computer CoLtd
N/A
Richard WohlComputer And Technologies
64
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey. AMNEAL PHMCTCLS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6000 people. Amneal Pharmaceuticals (2DT) is traded on Frankfurt Exchange in Germany and employs 7,000 people.

Management Performance

Amneal Pharmaceuticals Leadership Team

Elected by the shareholders, the Amneal Pharmaceuticals' board of directors comprises two types of representatives: Amneal Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amneal. The board's role is to monitor Amneal Pharmaceuticals' management team and ensure that shareholders' interests are well served. Amneal Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amneal Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sanjay Jain, President - India
Anastasios Konidaris, Chief Financial Officer, Senior Vice President
Shlomo Yanai, Independent Director
John Kiely, Independent Director
Gautam Patel, Director
Nikunj Patel, Head Ltd
Chintu Patel, Co-Chief Executive Officer, Co-Founder, Director
Stephen Manzano, Senior Vice President General Counsel & Corporate Secretary
Sanjiv Patel, VP Operations
Emily Alva, Independent Director
Paul Meister, Independent Chairman of the Board
Nikita Shah, Chief Human Resource Officer, Senior Vice President
Jason Esq, Chief VP
Andrew Boyer, Executive Vice President - Commercial Operations
Anthony DiMeo, Director Relations
Joseph Greer, Senior Vice President - Global Quality Management
Apurva Saraf, Senior Vice President - Corporate Development
RPh RPh, CoCEO CoFounder
J Buchi, Independent Director
Chirag Patel, President, Co-Chief Executive Officer, Director
Ted Nark, Independent Director
Joseph Todisco, Senior Vice President - Specialty Commercial
Jeffrey George, Independent Director

Amneal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amneal Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Amneal Stock

Amneal Pharmaceuticals financial ratios help investors to determine whether Amneal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amneal with respect to the benefits of owning Amneal Pharmaceuticals security.